HIGHLIGHTS
- who: Xiaocheng Li from the National and Kapodistrian University of Athens, Greece have published the article: Case report: Conversion therapy for advanced intrahepatic cholangiocarcinoma using PD-1 inhibitor plus S-1 and nab-paclitaxel, in the Journal: (JOURNAL)
- what: The case in the study shows that conversion therapy for advanced iCCA can be achieved using a PD-1 inhibitor plus S-1 and nab-paclitaxel; this triplet regimen is safe and effective.
- how: The results indicated that the FOLFOX regimen improved the overall survival rate by 14.5% at 12 months.
-
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.